Pakistan · Delayed Price · Currency is PKR BF Biosciences Statistics
Total Valuation
BF Biosciences has a market cap or net worth of PKR 13.08 billion. The enterprise value is 13.91 billion.
| Market Cap | 13.08B |
| Enterprise Value | 13.91B |
Important Dates
The next estimated earnings date is Tuesday, September 22, 2026.
| Earnings Date | Sep 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BF Biosciences has 88.33 million shares outstanding. The number of shares has increased by 18.25% in one year.
| Current Share Class | 88.33M |
| Shares Outstanding | 88.33M |
| Shares Change (YoY) | +18.25% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.13% |
| Float | 25.00M |
Valuation Ratios
The trailing PE ratio is 22.11.
| PE Ratio | 22.11 |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| PB Ratio | 2.55 |
| P/TBV Ratio | 2.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 44.01 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 23.51 |
| EV / Sales | 1.57 |
| EV / EBITDA | 11.16 |
| EV / EBIT | 14.23 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.99 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.38 |
| Debt / FCF | -7.96 |
| Interest Coverage | 13.92 |
Financial Efficiency
Return on equity (ROE) is 12.25% and return on invested capital (ROIC) is 10.68%.
| Return on Equity (ROE) | 12.25% |
| Return on Assets (ROA) | 7.05% |
| Return on Invested Capital (ROIC) | 10.68% |
| Return on Capital Employed (ROCE) | 14.27% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 16.56M |
| Profits Per Employee | 1.11M |
| Employee Count | 535 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, BF Biosciences has paid 420.44 million in taxes.
| Income Tax | 420.44M |
| Effective Tax Rate | 41.54% |
Stock Price Statistics
The stock price has decreased by -11.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -11.30% |
| 50-Day Moving Average | 141.51 |
| 200-Day Moving Average | 150.47 |
| Relative Strength Index (RSI) | 63.50 |
| Average Volume (20 Days) | 248,767 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BF Biosciences had revenue of PKR 8.86 billion and earned 591.76 million in profits. Earnings per share was 6.70.
| Revenue | 8.86B |
| Gross Profit | 3.74B |
| Operating Income | 977.88M |
| Pretax Income | 1.01B |
| Net Income | 591.76M |
| EBITDA | 1.25B |
| EBIT | 977.88M |
| Earnings Per Share (EPS) | 6.70 |
Balance Sheet
The company has 895.05 million in cash and 1.72 billion in debt, with a net cash position of -828.77 million or -9.38 per share.
| Cash & Cash Equivalents | 895.05M |
| Total Debt | 1.72B |
| Net Cash | -828.77M |
| Net Cash Per Share | -9.38 |
| Equity (Book Value) | 5.13B |
| Book Value Per Share | 58.04 |
| Working Capital | 2.29B |
Cash Flow
In the last 12 months, operating cash flow was 297.30 million and capital expenditures -513.91 million, giving a free cash flow of -216.61 million.
| Operating Cash Flow | 297.30M |
| Capital Expenditures | -513.91M |
| Depreciation & Amortization | 268.83M |
| Net Borrowing | -483.80M |
| Free Cash Flow | -216.61M |
| FCF Per Share | -2.45 |
Margins
Gross margin is 42.19%, with operating and profit margins of 11.04% and 6.68%.
| Gross Margin | 42.19% |
| Operating Margin | 11.04% |
| Pretax Margin | 11.43% |
| Profit Margin | 6.68% |
| EBITDA Margin | 14.07% |
| EBIT Margin | 11.04% |
| FCF Margin | n/a |
Dividends & Yields
BF Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.25% |
| Shareholder Yield | -18.25% |
| Earnings Yield | 4.52% |
| FCF Yield | -1.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BF Biosciences has an Altman Z-Score of 4.16 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.16 |
| Piotroski F-Score | 6 |